Use Of Long-acting Contraception Research Articles

Requirements or incentives by government for the use of long-acting contraceptives. Board of Trustees, American Medical Association.

Following the approval of the long-acting contraceptive levonorgestrel (the Norplant Contraceptive System) for use by women, government officials have required or proposed uses of levonorgestrel that are problematic. One court ordered a woman convicted of child abuse to use levonorgestrel as a condition of her probation; legislators have proposed that women on welfare be paid to use levonorgestrel. Court-ordered use of long-acting contraceptives because of child abuse raises serious questions about a person's fundamental rights to refuse medical treatment, to be free of cruel and unusual punishment, and to procreate. The state's compelling interest in protecting children from abuse may be served by less intrusive means than imposing contraception on parents who have committed child abuse. If government benefits were based on the use of long-acting contraceptives, individuals would have to assume a potentially serious health risk before receiving their benefits. Government benefits should not be made contingent on the acceptance of a health risk.

Requirements or incentives by government for the use of long-acting contraceptives. Board of Trustees, American Medical Association

Requirements or incentives by government for the use of long-acting contraceptives. Board of Trustees, American Medical Association

Return to ovulation following the use of long-acting injectable contraceptives: A comparative study

A comparative study was undertaken in twenty-four Mexican women who discontinued the use of depo-medroxyprogesterone acetate (DMPA) or norethisterone enanthate (NET-EN) to assess the time required for the return to menses and ovulation. All subjects were exposed to long-acting injectable contraceptives for at least one year, and were followed prospectively. Serum progesterone levels were determined weekly in all subjects beginning 3 months after the last progestogen injection. Mean time to return to ovulation occurred significantly earlier (p < 0.001) after NET-EN (2.6 months) as compared with DMPA (5.5 months). No correlation between the return to ovarian function and the duration of steroid exposure was found. The overall data was interpreted as demonstrating a clear-cut difference between the two long-acting progestogens in terms of ovulation suppression.

Serum phospholipid fractionation after the use of long-acting progestational contraceptives

The effect of the two long-acting progestational contraceptive injection, depot-medroxyprogesterone acetate (DMPA) and norethisterone onenathate (NET-OEN), on blood phospholipid fractions were studied in eighteen women. The post-injection results showed a significant increase in total serum phospholipids, serum lecithin and serum cephalins. Serum lysolecithin was significantly decreased while serum sphingomyelin showed no significant change. The mechanisms responsible for these phospholipid changes remain somewhat unclear. However deranged liver function may share in its explanation.

Liver function tests after the use of long-acting progestational contraceptives

Liver function tests were performed in 80 women who were taking depomedroxyprogesterone acetate (DMPA) and norethisterone oenanthate (NET-OEN) as contraceptives for different durations. No significant change was found in the thymol turbidity, zinc turbidity, serum alkaline phosphatase, serum bilirubin, serum glutamic oxalacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT). However, there were a significant decrease in the prothrombin activity and a significant impairment in the clearance of bromsulphthalein (BSP) in all the groups studied.